Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

Targeted therapies and immunotherapies have radically improved treatment for advanced
non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver …

PURPOSE Phase III studies of intravenous amivantamab demonstrated efficacy across
epidermal growth factor receptor (EGFR)–mutated advanced non–small cell lung cancer …

This phase III trial showed that amivantamab plus lazertinib led to significantly longer
progression-free survival and duration of response than osimertinib in previously untreated …

Background Amivantamab-lazertinib significantly prolonged progression-free survival (PFS)
versus osimertinib in patients with epidermal growth factor receptor (EGFR)-mutant …

Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET
amplification as a mechanism of resistance to first-line osimertinib have few treatment …

Living guidelines are developed for selected topic areas with rapidly evolving evidence that
drives frequent change in recommended clinical practice. Living guidelines are updated on …

Third-generation EGFR tyrosine kinase inhibitor (TKIs) have revolutionized the treatment
landscape for patients with non-small cell lung cancer (NSCLC) harboring EGFR activating …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

The past year has offered significant advancements in the field of non–small cell lung cancer
(NSCLC), both in the early and advanced disease settings. The identification of guideline …